PMS-CAPTOPRIL - TAB 25MG TABLET

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CAPTOPRIL

Dostopno od:

PHARMASCIENCE INC

Koda artikla:

C09AA01

INN (mednarodno ime):

CAPTOPRIL

Odmerek:

25MG

Farmacevtska oblika:

TABLET

Sestava:

CAPTOPRIL 25MG

Pot uporabe:

ORAL

Enote v paketu:

100/1000

Tip zastaranja:

Prescription

Terapevtsko območje:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Povzetek izdelek:

Active ingredient group (AIG) number: 0114954001; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

1998-06-17

Lastnosti izdelka

PRODUCT MONOGRAPH
PR
PMS-CAPTOPRIL
Captopril Tablets, USP
Film-Coated Tablets
12.5, 25, 50 and 100 mg
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite100
September 7, 2016
Montreal, Canada
H4P 2T4
www.pharmascience.com
Submission Control No: 197598
_pms-CAPTOPRIL Product Monograph _
_ _
_Page 2 of 31 _
PRODUCT MONOGRAPH
NAME OF DRUG
PR
PMS-CAPTOPRIL
Captopril Tablets, USP
Film-Coated Tablets
12.5, 25, 50 and 100 mg
THERAPEUTIC CLASSIFICATION
Angiotensin-Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Captopril is an angiotensin converting enzyme inhibitor which is used
in the treatment of
hypertension and heart failure.
The mechanism of action of captopril has not yet been fully
elucidated. It appears to lower blood
pressure and be an adjunct in the therapy of congestive heart failure
primarily through suppression
of the renin-angiotensin-aldosterone system; however, there is no
consistent correlation between
renin levels and response to the drug. Renin, an enzyme synthesized by
the kidneys, is released into
the circulation where it acts on a plasma globulin substrate to
produce angiotensin I, a relatively
inactive decapeptide. Angiotensin I is then converted by angiotensin
converting enzyme (ACE) to
angiotensin II, a potent endogenous vasoconstrictor substance.
Angiotensin II also stimulates
aldosterone secretion from the adrenal cortex, thereby contributing to
sodium and fluid retention.
Captopril prevents the conversion of angiotensin I to angiotensin II
by inhibition of ACE, a
peptidyldipeptide carboxy hydrolase.
ACE is identical to "bradykininase" and captopril may also interfere
with the degradation of the
vasodepressor peptide, bradykinin. However, the effectiveness of
captopril in therapeutic doses
appears to be unrelated to potentiation of the actions of bradykinin.
Increased concentrations of
bradykinin or prostaglandin E2 may also have a role in the therapeutic
effect of captopril, especially
in low-renin hypertension.
Inhibition of